Irritable Bowel Syndrome (IBS) is one of the most prevalent gastrointestinal disorders worldwide, affecting more than 10% of the global adult population. Chronic abdominal pain, bloating, and irregular bowel habits substantially impair daily functioning. Many patients continue to seek effective interventions. DDS-1 and UABla-12 are two probiotic strains with clinical evidence specifically in IBS populations.
What distinguishes L. acidophilus DDS-1 and B. lactis UABla-12 from the broader probiotic market is straightforward: researchers evaluated both strains in a randomized controlled trial specifically in adults diagnosed with IBS, using abdominal pain as the primary outcome measure. YoungLong formulated Sensitive Capsule around this clinical evidence, selecting DDS-1 and UABla-12 as its core probiotic strains. The formulation additionally carries Monash University Low FODMAP Certified status, independently verifying that it contains no fermentable carbohydrates at levels that aggravate gut sensitivity.
DDS-1 and UABla-12 Clinical Trial Results
A randomized, double-blind, placebo-controlled, multi-center trial published in Nutrients (2020;12(2):363) examined both strains in 330 IBS adults over six weeks. Researchers applied Rome IV criteria for diagnosis. Each strain was assessed independently.
- Abdominal pain reduction: The DDS-1 group demonstrated an APS-NRS score change of -2.59, compared to -0.85 in the placebo group — a reduction more than three times greater (p=0.001). The UABla-12 group achieved a change of -1.56 (p=0.001).
- Significant responder rates: FDA guidance defines a significant responder as someone achieving ≥30% pain reduction. DDS-1 reached 52.3% and UABla-12 reached 28.2% — both surpassing placebo at 15.6%. (p<0.001 and p=0.031, respectively).
- Overall symptom severity: IBS-SSS scores dropped by 133.4 points in the DDS-1 group and 104.5 points in the UABla-12 group. Both groups improved across pain severity, pain duration, bloating, bowel habits, and quality of life. (p<0.001 vs. placebo for both).
- Stool consistency normalization: By day 42, 83.8% of DDS-1 participants and 75.5% of UABla-12 participants achieved normal stool form per Bristol Stool Scale (types 3-5). The placebo group showed no statistically significant change.
Why DDS-1 and UABla-12 Were Selected for a Sensitive Gut
Two aspects of this trial design are particularly relevant. First, the trial established abdominal pain as the primary endpoint — directly addressing IBS's most defining and disruptive symptom rather than a secondary proxy measure. Second, DDS-1 and UABla-12 were evaluated in separate trial arms, each reaching independent statistical significance. This separation confirms that the two strains achieve efficacy through distinct mechanisms, making them complementary rather than redundant in a combined formulation.
YoungLong Sensitive Capsule applies this evidence directly. The formulation prioritizes strain-specific clinical validation over broad-spectrum diversity. Low FODMAP certification ensures the product avoids reintroducing the gut irritants it targets.
DDS-1 and UABla-12 : Frequently Asked Questions
a combined formulation of both strains demonstrated meaningful improvements in IBS symptomology
Q : What is the minimum duration of supplementation before evaluating efficacy?
A : In the clinical trial, statistically significant APS-NRS improvements were first observed at day 21 (week 3), with the most pronounced outcomes at day 42 (week 6). Microbiota composition varies between individuals. Allow at least four to six weeks before drawing conclusions about personal response.
Q : Is there evidence of benefit for participants with diarrhea-type symptoms?
A : The trial did not include subtype-stratified primary analysis. However, UABla-12 participants with diarrhea-type stool form at baseline saw a 42.9% reduction in diarrhea by day 42. In the DDS-1 group, normal stool form rates rose from 59% at baseline to 83.8% at day 42, indicating broad bowel normalization across symptom presentations.
Conclusion
L. acidophilus DDS-1 and B. lactis UABla-12 rank among the few probiotic strains with RCT-level evidence in IBS populations. Researchers evaluated each strain independently against placebo, with abdominal pain as the primary outcome. Both strains demonstrated statistically significant improvements across abdominal pain, overall symptom severity, and stool consistency. Low FODMAP certification provides an additional evidence-based criterion relevant to IBS management. YoungLong formulated Sensitive Capsule on this evidence base.
